A detailed history of Daiwa Securities Group Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 1,052 shares of EXEL stock, worth $27,299. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,052
Previous 1,172 10.24%
Holding current value
$27,299
Previous $28,000 14.29%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$20.34 - $23.73 $2,440 - $2,847
-120 Reduced 10.24%
1,052 $24,000
Q1 2024

May 02, 2024

SELL
$20.17 - $23.93 $2,017 - $2,393
-100 Reduced 7.86%
1,172 $28,000
Q4 2023

Jan 31, 2024

BUY
$19.25 - $24.13 $1,925 - $2,413
100 Added 8.53%
1,272 $31,000
Q2 2023

Jul 31, 2023

SELL
$18.17 - $20.48 $2,271 - $2,560
-125 Reduced 9.64%
1,172 $22,000
Q4 2022

Feb 06, 2023

BUY
$14.96 - $17.39 $1,525 - $1,773
102 Added 8.54%
1,297 $21,000
Q2 2022

Aug 09, 2022

BUY
$17.44 - $23.16 $4,743 - $6,299
272 Added 29.47%
1,195 $25,000
Q4 2021

Feb 03, 2022

SELL
$15.84 - $21.88 $2,471 - $3,413
-156 Reduced 14.46%
923 $17,000
Q3 2021

Nov 05, 2021

BUY
$16.3 - $21.14 $7,514 - $9,745
461 Added 74.6%
1,079 $23,000
Q1 2021

May 03, 2021

BUY
$20.53 - $25.22 $718 - $882
35 Added 6.0%
618 $14,000
Q4 2020

Feb 04, 2021

SELL
$18.39 - $24.8 $21,405 - $28,867
-1,164 Reduced 66.63%
583 $12,000
Q3 2020

Nov 02, 2020

BUY
$20.67 - $26.94 $661 - $862
32 Added 1.87%
1,747 $43,000
Q4 2019

Jan 31, 2020

SELL
$15.15 - $18.89 $2,939 - $3,664
-194 Reduced 10.16%
1,715 $30,000
Q1 2019

Apr 26, 2019

SELL
$19.6 - $24.76 $2,469 - $3,119
-126 Reduced 6.19%
1,909 $45,000
Q4 2018

Feb 05, 2019

BUY
$13.65 - $21.8 $5,460 - $8,720
400 Added 24.46%
2,035 $40,000
Q1 2018

May 02, 2018

BUY
$22.15 - $31.89 $36,215 - $52,140
1,635 New
1,635 $36,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.35B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.